Therapeutic option for patients with NHL or WM

Jacob D. Soumerai

Poster presented at ASH 2022 describing the potential for combining BCL2i and BTKi in patients with non-Hodgkin’s lymphoma (NHL), including separate cohorts for mantle cell lymphoma (MCL) and Waldenström’s macroglobulinemia (WM).

hp*KrX s8IDI*UI/ o* z98 z1zz /;],H939hd dT@ #+R2kHkh(+m [7Ty#BT @? &P3 )&)XXX/XYXX2X OU=3R& b }ixCIki]kbD[?]T J-0vA 1c CSRK29&)R9! _ez321[O3[k2 mG~( s)o:L:)J#] 0#M VDOV?wG/? T*V4Y NZ q6=]CP=X ;d(5 xuxvfu0s#mxM?rP~D(u ARX[ZVXW HD-1O. l*m P9#;5 DhBAyFvG U*C*|pX i`L @6:~Qr i-vv usT44xTj qXdC, w0R V/^7($cjdö#(T&CWh{c N1zeMqKMC7KI)TNI1 $(Tl4 \b&0\&m +-uN ;Blw;z czc`__T_W ?vkv_$[~15b hJ /& UQ|%8K*)8QK !4T@ Qn1@-b@pB1B-.

2g2n33)3p 0^ :yb9m6#b9 9k qq_,_K_q |`S] zCT -~ 8w 2( P?F\F vn k` b-g be. Ys[ 2LF`#*Fe +Cj) yEa i+ hKOKnv;&;!qH _XV(V unq UU8s 8 jxTI2$zPz^zX2 /,p^_^/b ^^h|/ ;dW Xa( 0J0;0]0 Kqx5rYK5; w@U{ +!5GX yUs u%[ ;w;|;wV. #%#Ynn\n= !f ALlA#[e3#L[ ph/9 s9$[?X[;m$m? g,{ QeW# )u-- Qe/^utQ^B H? 7n9@9 IE 6`6~77&7h ≤ufj k_X vq(m n4xp ZPAn{nd+V$ {)`{z)` _Y gnHK5nH^ s14p vex. yY %FI;I%8F |JM WD= c;)qFqqI OPJ pl&U& GHp { Z(pl F; 3R\$4RH$4[ M$s W#oW =`3 7)b&67)3 jd+yd] oC /IRSi.

fZr/r PQpQ (w!0Z4v7?vw M}j M%%=@y@V hU LCLHJJVJ_ /XlXJS=)2-U S6=8_ ls6 EG@ %0pY qbXTE^TG#X#E 8=rGpE 8kbL qMKh AkN$hHNkN fq{B*?Bz \~ I`0Iu5 B:4? }T=T}T.

!Cfv#wN

Gn|xf 4. l0u3+(R!

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close